Nrf2 Regulates Anti-Inflammatory A20 Deubiquitinase Induction by LPS in Macrophages in Contextual Manner

Haranatha R. Potteti 1,†, Lalith K. Venkareddy 1,‡, Patrick M. Noone 1, Aparna Ankireddy 1, Chandramohan R. Tamatam 1, Dolly Mehta 2, Chinnaswamy Tiruppathi 2 and Sekhar P. Reddy 1,3,4,*

1 Departments of Pediatrics, University of Illinois, Chicago, IL 60612, USA; phreddy@uic.edu (H.R.P.); lalith15@uic.edu (L.K.V.); pnoone2@uic.edu (P.M.N.); aparrnot@uic.edu (A.A.); tamatam@uic.edu (C.R.T.)
2 Department of Pharmacology, University of Illinois, Chicago, IL 60612, USA; dmehta@uic.edu (D.M.);
tiru@uic.edu (C.T.)
3 Department of Pathology, University of Illinois, Chicago, IL 60612, USA
4 University of Illinois Cancer Center, University of Illinois, Chicago, IL 60612, USA
* Correspondence: sreddy03@uic.edu
† Equally contributed.

Abstract: The aberrant regulation of inflammatory gene transcription following oxidant and inflammatory stimuli can culminate in unchecked systemic inflammation leading to organ dysfunction. The Nrf2 transcription factor dampens cellular stress and controls inflammation by upregulating antioxidant gene expression and TNFα-induced Protein 3 (TNFAIP3, aka A20) deubiquitinase by controlling NF-κB signaling dampens tissue inflammation. Here, we report that Nrf2 is required for A20 induction by inflammatory stimuli LPS in monocyte/bone marrow derived macrophages (MDMΦs) and was not restored by antioxidant supplementation. Nrf2 deficiency markedly impaired LPS-induced A20 expression was significantly lower in Nrf2−/− MDMΦs and was not restored by antioxidant supplementation. Nrf2 deficiency markedly impaired LPS-stimulated A20 mRNA expression Nrf2−/− MDMΦs and ChIP assays showed Nrf2 enrichment at the promoter Nrf2−/− MDMΦs upon LPS stimulation, demonstrating that Nrf2 directly regulates A20 expression. Contrary to MDMΦs, LPS-stimulated A20 expression was not largely impaired in Nrf2−/− LDMΦs ex vivo and in vivo and ChIP assays showed lack of increased Nrf2 binding at the A20 promoter in LDMΦ following LPS treatment. Collectively, these results demonstrate a crucial role for Nrf2 in optimal A20 transcriptional induction in macrophages by endotoxin, and this regulation occurs in a contextual manner.

Keywords: Inflammation; deubiquitinase; macrophages; endotoxin; lung

1. Introduction

A counterbalance between pro- and anti-inflammatory gene transcription is crucial for normal homeostasis after septic shock. Aberrant regulation of this balance culminates in unchecked systemic inflammation leading to organ dysfunction. The Nrf2 transcription factor dampens cellular stress and controls inflammation by upregulating antioxidant gene expression and TNFα-induced Protein 3 (TNFAIP3, aka A20) deubiquitinase by controlling NF-κB signaling dampens tissue inflammation. Here, we report that Nrf2 is required for A20 induction by inflammatory stimuli LPS in monocyte/bone marrow derived macrophages (MDMΦs) but not in lung-macrophages (LDMΦs). LPS-induced A20 expression was significantly lower in Nrf2−/− MDMΦs and was not restored by antioxidant supplementation. Nrf2 deficiency markedly impaired LPS-stimulated A20 mRNA expression Nrf2−/− MDMΦs and ChIP assays showed Nrf2 enrichment at the promoter Nrf2−/− MDMΦs upon LPS stimulation, demonstrating that Nrf2 directly regulates A20 expression. Contrary to MDMΦs, LPS-stimulated A20 expression was not largely impaired in Nrf2−/− LDMΦs ex vivo and in vivo and ChIP assays showed lack of increased Nrf2 binding at the A20 promoter in LDMΦ following LPS treatment. Collectively, these results demonstrate a crucial role for Nrf2 in optimal A20 transcriptional induction in macrophages by endotoxin, and this regulation occurs in a contextual manner.
However, increased NF-κB levels persist under inflammatory conditions, suggesting A20 expression and/or functional activity is sub-optimal and leads to insufficient termination of NF-κB signaling. Thus, delineating the exact mechanisms underlying optimal A20 transcription may provide novel insights into heightened inflammation caused by microbial and nonmicrobial insults.

Nuclear factor erythroid 2-like 2 (NFE2-L2 or aka Nrf2) is a transcription factor that activates gene expression required for cytoprotection, tissue regeneration, and host defense through the antioxidant response element (ARE) [13,14]. Kelch-like ECH-associated Protein 1 (Keap1) is the endogenous negative regulator of Nrf2. It retains the latter in the cytosol and enables its proteasomal degradation by the Cul3-ubiquitin ligase system, thereby limiting Nrf2-regulated gene transcription. Stressful stimuli causing oxidative or electrophilic modifications of cysteine residues in Keap1 impede Nrf2 degradation and foster its subsequent nuclear accumulation, leading to enhanced cytoprotective gene expression [13,14]. We have previously shown that Nrf2 confers protection against infectious (e.g., endotoxin) and oxidant stress (e.g., hyperoxia and mechanical ventilation) induced lung inflammatory injury [15–17]. Impaired resolution of lung inflammation in Nrf2-deficient mice is observed after oxidant-induced acute lung injury [18]. Nrf2 negatively modulates LPS-stimulated NF-κB activity and thereby suppresses inflammation during septic shock [15]. We tested whether or not Nrf2 controls the inflammatory response by modulating A20 expression levels. Here, we report that Nrf2 positively regulates A20 expression in response to pro-inflammatory stimuli (LPS and TNFα), and that it directly binds to the endogenous A20 promoter encompassing ARE. These results demonstrate a crucial role for Nrf2 in the regulation of optimal A20 transcriptional induction by inflammatory stimuli and that this regulation is distinctly modulated in monocyte-derived and lung tissue-resident macrophages.

2. Materials and Methods
2.1. Mice, LPS Exposure, and Lung Cell Isolation

Wildtype (C57BL6, WT) and Nrf2−/− mice (8–16 wk males) under anesthesia were instilled intratracheally with sterile PBS (vehicle) or 10 µg of LPS (L4005; Sigma-Aldrich, St Louis, MO, USA). Mice were killed after 6 h and lung derived (resident) macrophages (LDMΦs) were isolated as previously described [19,20]. Briefly, mice were euthanized, sacrificed and lungs were instilled with 1 mL of RPMI-1640 medium containing dispase solution (Roche Applied Science, Penzberg, Germany) (0.8 U/mL) and collagenase type II (1 mg/mL) (Thermo-Fisher Scientific, Waltham, MA, USA), and incubated at 37 °C for 30 min. Lung tissue was gently teased in DMEM with 10% FBS supplemented with HEPES and antibiotics, filtered, plated on 6-well plates, and incubated at 37 °C for 30 min. Supernatant was removed, and attached macrophages were lysed with TRIzol.

For ex vivo studies, LDMΦs isolated from naïve wildtype (Nrf2+/+) and Nrf2−/− mice (8–16 weeks, males and females) separately as above and then incubated in RPMI medium with 1% FBS for at least 1 h prior to treatment with 100 ng/mL LPS (L2637; Sigma-Aldrich) or 10 ng/mL TNFα (410-MT, Biotech/R&D Systems, Minneapolis, MN, USA) and then lysed for RNA isolation. Experiments with mice were performed according to the protocol guidelines approved by the animal care and use committee at University of Illinois at Chicago.

2.2. Cell Culture

BMDMΦs were isolated from WT and Nrf2−/− mice (8–16 weeks, males and females) separately and cultured in RPMI medium supplemented with 15% L929 medium in petri-dishes for 5–6 days using standard protocol. One day prior to treatment, cells were lifted and plated on 6-well culture plates for at least 16–18 h. Cells cultured in medium with 1% FBS for 2 h and then treated with 100 ng/mL LPS or 10 ng/mL TNFα. MH-S (a murine alveolar macrophage cell line) were cultured in RPMI medium with 10% FBS and antibiotics. After 2 h serum starvation (1% FBS), MH-S were either treated with vehicle...
(PBS) or LPS (100 ng/mL). Mouse embryonic fibroblasts (MEFs) derived from wildtype and Nrf2$^{-/-}$ mice were cultured in Iscove’s modified Dulbecco’s medium with 10% FBS and antibiotics as detailed elsewhere [21]. MEFs were cultured in medium with 1% FBS for 2 h prior to treatment with LPS (500 ng/mL) or TNFα (10 ng/mL).

2.3. Chromatin Immunoprecipitation (ChIP) Assays

ChIP and qPCR analysis were performed using an EZ-ChIP assay kit (17-295, EMD Millipore, Burlington, VT, USA). Briefly, BMDMΦs or MH-S cells treated with LPS were crosslinked with formaldehyde, and chromatin was prepared according the protocol. Diluted and precleared chromatin was incubated with Nrf2 antibodies (SC-365949, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), IgG or RNA Pol II antibodies (17-295, EMD Millipore) for 18 h at 4°C with rotation. Samples were incubated with protein A-agarose, washed and bound DNA was eluted. Immunoprecipitated DNA was amplified by qPCR using murine A20 promoter (Accession KX869907) specific primers: Forward, 5′-CTATTGCTGCTTGTAGCATC-3′ and Reverse, 5′-GTTTGTCAGTGATCCAAGTTTGT-3′.

2.4. Quantitative Real-Time PCR

RNA was isolated using the TRIzol reagent (Thermo Fisher). cDNA was prepared using qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly Hills, CA, USA) and fast SYBR green quantitative real-time PCR (qRT-PCR) assay (Thermo Fisher) was performed using primers: A20 (Tnfaip3 NM_009397, F: CAGTGGAGGGCAAACT, R: GCAGTGGCAGAAACTCCCTC), Tnfaip2 (NM_009396, F: AGGAGGATCTGGCGGAAGA, R: GGCAGTGGAAGCTCTAATCG), Tnfaip1 (NM_0011593920, F: GGTGCAA-CAACTCGTG, R: GTGCCTTTCCACACTCGTCTA), Nqo1 (NM_008706, F: TTCTCTGGGAGCAAAGATCTAAGT, R: GAGAAGACACAGATTCCAATCCCAG), and β-actin (NM_007393, F: CTGAGAAGATGACGTTGCTA, R: GCGCAGCTCGTAGTATGC). β-actin was used as reference to normalize and calculate the expression levels of the target genes. Relative fold change was calculated using WT control group or PBS treated cells.

2.5. Immunoblotting

Cells were homogenized in RIPA buffer (R0278, Sigma, St. Louis, MI, USA) with protease cocktail inhibitor (P8340, Sigma), and extract (~40 µg) was separated, blotted, and probed with A20 antibodies (C4625, Cell Signaling Technologies, Danvers, MA, USA) and β-actin antibodies (A5441, Sigma Aldrich). Immunoblots were developed using the HyGlo ECL kit (E2400, Denville Scientific Inc., Metuchen, NJ, USA) and visualized by Bio-Rad Gel Doc system.

2.6. Statistical Analysis

Two-way ANOVA with Tukey’s multiple comparisons test using GraphPad was used to calculate the significance between WT and Nrf2$^{-/-}$ genotypes. Otherwise, Student’s t-test was used for comparisons with PBS controls. Error bars represent SD. p <0.05 are considered as significant.

3. Results

3.1. Nrf2-Deficiency Impairs LPS-Induced A20 Expression in Monocyte-Derived Macrophages

To evaluate whether Nrf2 regulates A20 expression, BMDMΦs from wildtype (WT) and Nrf2$^{-/-}$ mice (males) were isolated and treated with PBS (control, 0 h), or with LPS for 0.5 h or 6 h. Protein extracts were isolated and A20 levels were analyzed by immunoblot analysis. As shown in Figure 1A, LPS stimulated A20 expression by 0.5 h compared to control (untreated) cells. In Nrf2$^{-/-}$ BMDMΦs, basal level A20 expression is low compared to wildtype cells and was not induced by LPS, demonstrating that Nrf2 regulates A20 expression. To determine whether antioxidant supplementation to Nrf2$^{-/-}$ cells will restore A20 induction by LPS, both wildtype and Nrf2$^{-/-}$ BMDMΦs were cultured...
overnight with N-acetylcysteine (NAC) and then treated with LPS for 1 h. Cells were lysed and A20 expression was analyzed by immunoblot analysis (Figure 1B). Both basal and LPS-stimulated A20 expression were not restored in Nrf2−/− BMDMΦs supplemented with NAC. Likewise, proteasomal inhibition did not restore LPS-stimulated A20 expression levels in Nrf2−/− cells following LPS stimulation (data not shown). These results suggest that Nrf2 regulates A20 expression directly at the transcriptional level. To examine whether Nrf2 directly regulates A20 transcription, BMDMΦs isolated from WT and Nrf2−/− mice of both genders (males and females) separately were treated with PBS (control, 0 h), or with LPS for 1 h or 6 h. RNA was isolated and A20 mRNA levels were analyzed by qRT-PCR. As shown in Figure 1C, LPS strongly stimulated A20 expression by 1 h and expression remained high above basal level up to 6 h compared to control. In Nrf2−/− BMDMΦs, LPS-stimulated A20 mRNA levels were significantly lower than in WT counterparts.

Figure 1. LPS-induced A20 expression is lower in Nrf2-deficient BMDMΦs. (A) Cell extracts were isolated from wildtype (WT) and Nrf2−/− bone marrow-derived macrophages (BMDMΦs) treated with LPS (100 ng/mL), blotted and probed with A20 antibodies. (B) WT and Nrf2−/− BMDMΦs were treated with 5 mM N-acetylcysteine (NAC) for 16 h and then treated with LPS for 1 h. Cell extracts were probed A20 antibodies. Note that blotted membranes were cut at ~50 kD and top and bottom portion of the blots were probed with A20 and β-actin antibodies, respectively. (C) WT and Nrf2−/− BMDMΦs isolated from male and female mice in separate experiments were treated with LPS (100 ng/mL) or TNFα (10 ng/mL) for 1 h or 6 h. Total RNA was isolated for A20 mRNA expression analysis. Values of PBS controls used in right panel are the same as those in left panel. * versus PBS; § versus WT counterparts. LPS and TNFα stimulated A20 mRNA expression levels in BMDMΦs of male and female mice are shown in Figure S1.

We examined whether Nrf2 deficiency broadly affects A20 induction by inflammatory stimuli or if these effects were limited to LPS. To evaluate this aspect, WT and Nrf2−/− BMDMΦs isolated above were treated with TNFα for 1 h or 3 h, and A20 expression was analyzed by qRT-PCR. A20 was originally identified as a TNFα-inducible gene (TNFAIP3). As anticipated, TNFα stimulated A20 expression in WT BMDMΦs by 1 h, but the magnitude of induction was lower in Nrf2−/− cells (Figure 1C). However, TNFα stimulated A20 expression was significantly elevated in Nrf2−/− BMDMΦs by 6 h compared to WT counterparts. Note that BMDMΦs isolated from both males and females showed a similar response in the context of LPS- and TNFα-stimulated A20 expression regulation by Nrf2 (see Supplementary Figure S2).
3.2. A20 Induction by TNFα in Embryonic Fibroblasts is Regulated by Nrf2

Next we examined A20 expression regulation by Nrf2 in another cell type, using embryonic fibroblasts derived from WT and Nrf2−/− mice. Mouse embryonic fibroblasts (MEFs) were treated with LPS or TNFα for 1 h or 6 h, RNA was isolated, and A20 expression was analyzed by qRT-PCR. As shown in Figure 2A, LPS did not significantly stimulate A20 expression in WT and Nrf2−/− cells. Lack of LPS induced A20 mRNA expression was anticipated as these cells compared to macrophages are known to respond poorly to LPS. However, TNFα-strongly stimulated A20 expression, which was markedly lower in Nrf2−/− MEFs than in WT counterparts (Figure 2B). Basal A20 expression levels were not affected by Nrf2-deficiency (Figure 2A,B). These results demonstrate that Nrf2 regulates A20 expression in multiple cell types in response to pro-inflammatory stimuli.

**Figure 2.** Nrf2 deficiency impairs TNFα stimulated A20 induction in embryonic fibroblasts. Wildtype (WT) MEFs and Nrf2−/− MEFs were treated with 500 ng/mL LPS (A) or 10 ng/mL TNFα (B), RNA isolated and A20 mRNA expression analyzed. * versus PBS; § versus WT counterparts. Values of PBS controls are from panel A as TNFα and LPS treatments were carried out in parallel.

3.3. Nrf2 Does Not Regulates LPS- and TNFα-Stimulated A20 Expression in Lung Macrophages Ex Vivo

Previous studies have shown distinct regulation of inflammatory cytokine gene expression in lung resident macrophages compared to infiltrated macrophages (see discussion). We therefore examined A20 expression regulation by LPS and TNFα in lung derived macrophages (LDMΦs). The lungs from naïve WT and Nrf2−/− males and female mice were separately digested and macrophages were isolated as detailed in methods. We used this method mainly to minimize perturbations of lung macrophages and to mimic their naïve state in vivo [19,20]. LDMΦs were treated with LPS or TNFα for 1 h or 3 h, RNA was isolated and A20 mRNA expression was analyzed by qRT-PCR. As shown in Figure 3, LPS-stimulated A20 expression between WT and Nrf2−/− cells was comparable (Figure 3A). Additionally, TNFα-stimulated A20 expression was modestly lower in Nrf2−/− LDMΦs than in WT counterparts (Figure 3B). LDMΦs isolated from both males and females showed a similar response in the context of A20 expression regulation by LPS and TNFα (Supplementary Figure S3). Note that, due to variability of the magnitude of A20 induction by LPS between LDMΦs of males and females, combined values do not show significance at the 1 h time point, contrary to their individual comparison (Supplementary Figure S3).
Figure 3. Nrf2 does not regulate LPS-stimulated A20 transcriptional induction in LDMΦs ex vivo. Lungs from wildtype (WT) and Nrf2−/− mice (males and females, 2-3 mice) were harvested and digested separately for macrophage isolation as outlined in schema (see methods for details). Lung-derived macrophages (LDMΦs) were treated with 100 ng/ml LPS (A) or 10 ng/ml TNFα (B) for 1 h or 3 h. Values of PBS controls used are the same as those used in panel A, as TNFα was used along with LPS treatment. LPS and TNFα stimulated A20 expression levels in BMDMΦs of male and female mice are shown in Figure S2. (C) Tnfaip1, Tnfaip2 and Nqo1 mRNA expression in LDMΦs isolated from male mice treated with LPS and TNFα ex vivo for 1 h is shown. * versus PBS; § versus WT counterparts.

We next analyzed the expression levels of Tnfaip1 (BCR E3-ubiquitin ligase complex) and Tnfaip2 in LDMΦs isolated from male mice treated with LPS or TNFα for 1 h (Figure 3C). We found that both of them were strongly induced by LPS in WT cells, but their induction was impaired in Nrf2−/− cells. In contrast to LPS, both Tnfaip1 and Tnfaip2 expression was not induced by TNFα. To verify that Nrf2 is functionally active in LDMΦs, we have quantified the levels of Nrf2 putative target Nqo1 (Figure 3C). As anticipated, Nqo1 expression was markedly lower in Nrf2−/− LDMΦs, and its expression in WT (Nrf2+/+) cells was not altered by LPS or TNFα. These results suggest that Nrf2 distinctly regulates Tnfaip1, Tnfaip2 and Tnfaip3 expression in LDMs in response to inflammatory stimuli.

3.4. Nrf2 Deficiency Augments LPS-Stimulated IL-1β Expression in Both BMDMΦs and LDMΦs

We next examined whether Nrf2 deficiency distinctly affects inflammatory cytokine gene expression in response to LPS in BMDMΦs and LDMΦs by measuring IL-1β expression levels. As shown in Figure 4, LPS-stimulated IL-1β expression in Nrf2−/− BMDMΦs was greater than in WT counterparts. Likewise, IL-1β induction by LPS was more evident in Nrf2−/− LDMΦs compared to WT LDMΦs. These results suggest that Nrf2 dampens LPS-stimulated IL-1β expression levels in both BMDMΦs and LDMΦs. In contrast to LDMΦs, however we found that IL-1β expression was high in Nrf2−/− BMDMΦs compared to WT BMDMΦs under basal state.
Figure 4. Nrf2 deficiency augments LPS-stimulated IL-1β expression in both BMDMΦs and LDMΦs. IL-1β mRNA expression levels in BMDMΦs and LDMΦs isolated from male and female mice and treated with LPS for 6 h (BMDMΦs) and 3 h (LDMΦs), as in Figures 2 and 5, was analyzed by qRT-PCR. * versus PBS; § versus WT counterparts. LPS-stimulated IL-1β mRNA levels in BMDMΦs of male and female mice are shown in Figure S3.

3.5. Nrf2 Does Not Regulate LPS-Stimulated A20 Expression in Lung Derived Macrophages In Vivo

To examine Nrf2 regulated A20 expression in LDMΦs in vivo, WT and Nrf2<sup>−/−</sup> mice (males) treated oropharyngeally with PBS or LPS (10 µg/mouse) for 6 h. We chose this time point to determine direct effects of Nrf2 on A20 transcriptional induction, which occurs rapidly following LPS stimulation. Moreover, we chosen this early time point to minimize the recruitment of infiltrated monocytes in the lung following LPS exposure. Mice were immediately sacrificed, lungs digested, macrophages isolated, and A20 mRNA expression was analyzed by qRT-PCR. As shown in Figure 5, LPS-stimulated A20 expression in LDMΦs is comparable between WT and Nrf2<sup>−/−</sup> cells. Tnfaip2 but not Tnfaip1 expression was stimulated by LPS, but the induction was comparable between LDMΦs of two genotypes. IL-1β expression was more in LDMΦs of LPS treated Nrf2<sup>−/−</sup> mice compared to WT counterparts, but this cytokine expression was comparable between WT and Nrf2<sup>−/−</sup> mice treated with PBS.

Figure 5. Nrf2 does not regulate A20 induction by LPS in LDMΦs in vivo. WT and Nrf2<sup>−/−</sup> mice (males) were treated oropharyngeally with LPS (10 µg/mouse) for 6 h, and immediately sacrificed, lungs were perfused, harvested separately from 2-3 mice and lung digest from each mouse was plated on two different culture (60 mm) dishes, and attached macrophages were used for RNA isolation and cDNA preparation. A20 (Tnfaip3), Tnfaip1, Tnfaip2 and IL-1β expression was analyzed by qRT-PCR. * versus PBS.
3.6. Nrf2 Binds to the Endogenous A20 Promoter in BMDMΦs But Not in LDMΦs

To further examine whether Nrf2 directly regulates A20 transcription, BMDMΦs were treated with LPS for 30 min or 60 min and chromatin was cross-linked. Chromatin fragments were immunoprecipitated with anti-Nrf2 antibodies and immunoprecipitated DNA fragments were quantified using primers encompassing the Nrf2 putative binding site, ARE, located at the A20 proximal promoter (Figure 6A). Nrf2 binding was increased at the promoter by 30 min following LPS stimulation and remained high up to 60 min (Figure 6B). RNA Pol II antibodies were used in ChIP assays to demonstrate the A20 promoter is transcriptionally active, and IgG was used as a negative control to demonstrate specific binding (data not shown). Collectively, these results and above demonstrate that Nrf2 binds to the A20 promoter and regulates its transcription.

Figure 6. Nrf2 binding at the A20 promoter in LPS treated BMDMΦs and LDMΦs. (A) Schema represents position of the antioxidant response element (ARE), and NF-kB and AP-1 binding sites of the murine A20 promoter. BMDMs (B) and MH-S cells (C) were treated with PBS or LPS (100 ng/mL) for 30 or 60 min, crosslinked and ChIP assays were performed using Nrf2 antibodies and murine A20 promoter specific forward and reverse primers (arrows) flanking the ARE. The relative Nrf2 binding was calculated using PBS control samples values as one arbitrary unit. (D) MH-S cells treated with LPS (100 ng/mL) for 1 h or 6 h. RNA isolated and A20 mRNA expression was analyzed. * versus PBS.

To determine the nature of Nrf2 binding at the A20 promoter in alveolar macrophages, we performed ChIP assays in a murine alveolar macrophage cell line, MH-S. We choose these cells in lieu of primary LDMs due to the requirement of large number cells for ChIP assays. MH-S cells were stimulated with LPS for different periods, chromatin was cross-linked, immunoprecipitated with Nrf2 antibodies, and ChIP-qPCR was performed as above. Contrary to BMDMΦs, Nrf2 binding in MH-S cells was modestly but not significantly increased at the promoter region by 60 min after LPS treatment (Figure 6C). To verify that A20 mRNA expression is induced by LPS in this cell type, we have analyzed A20 mRNA expression in LPS-treated MH-S cells. Indeed, LPS strongly stimulated A20 mRNA expression in MH-S cells by 1 h (Figure 6D), demonstrating its inducibility in these cells. Moreover, Nrf2 expression is detectable in MH-S cells (data not shown). These results suggest Nrf2 recruitment to the A20 promoter does not occur strongly in alveolar macrophages following LPS stimulation.

4. Discussion

The present study demonstrates a novel function for Nrf2 in upregulating A20 deubiquitinase expression levels in macrophages in response to inflammatory stimuli. We found that Nrf2 directly upregulates A20 expression by binding to its promoter bearing
the ARE. Furthermore, we observed that Nrf2 mediated A20 expression in macrophages is cell- and context-specific, as evidenced by the fact that A20 induction by LPS is Nrf2 dependent in monocyte (bone marrow)-derived macrophages but not in lung tissue resident macrophages. Previously, we have shown that deletion of Nrf2 in mice worsens endotoxemia and sepsis, accompanied by increased levels of NF-κB activity and inflammatory cytokine gene expression in the lung [15]. A20 terminates NF-κB and MAP (JNK and p38) kinase signaling by removing K-63-linked poly-ubiquitin chains on NEMO/IKKγ, TRAF2 and TRAF6 [4,5]. Because LPS and TNFα induced A20 transcription in macrophages is regulated by Nrf2, we propose that excessive inflammation suppression by Nrf2 is multi-faceted and occurs, at least in part, via A20 dependent termination of NF-κB and MAP kinase signaling. Concerted communication between these signaling pathways is necessary for maintaining homeostasis following microbial infection or exposure to pro-inflammatory insults.

A20 transcriptional induction in macrophages generally peaks by 1–3 h in response to inflammatory stimuli (e.g., LPS and TNFα). Our studies performed revealed an important role for Nrf2 in the transcriptional upregulation of A20 in macrophages in response to acute inflammatory stimuli. Both mouse and human A20 promoters bear Nrf2 putative binding sites (i.e., AREs), and ChIP-qPCR assays showed enrichment of Nrf2 binding at the A20 promoter in murine BMDMs immediately following LPS treatment, accompanied by A20 transcription. However, our results demonstrate that Nrf2 regulated A20 expression operates distinctly and contextually in macrophages, as we found that Nrf2 does not regulate LPS-stimulated A20 expression in lung tissue resident macrophages. Consistent with this result, Nrf2 binding at the A20 promoter in LPS-stimulated alveolar macrophages was not markedly increased above basal level when compared to LPS-stimulated BMDMs (Figure 6). ChIP-qPCR assays performed with RNA polymerase II showed enriched binding at the promoter in alveolar macrophages treated with LPS (data not shown), suggesting that lack of increased Nrf2 binding at the A20 promoter following LPS stimulation was likely not due to lack of accessibility of chromatin to immunoprecipitation. We found reduced basal levels of Nqo1 mRNA expression in Nrf2−/− LDMΦs (Figure 5), verifying the lack of Nrf2 function in this cell type. LPS did not significantly stimulate A20 expression in MEFs as they are known to be poor responders to endotoxin due to decreased expression levels of LPS receptor, TLR4, as compared to macrophages. However, TNFα stimulated A20 expression is significantly lower in Nrf2−/− cells compared to wildtype counterparts (Figure 2). We found that Nrf2 does not regulate TNFα-induced A20 expression in LDMΦs but regulates expression of other genes such as Tnfaip1 and Tnfaip2. Why Nrf2 does not regulate TNFα and LPS-stimulated A20 expression in lung macrophages is unclear and warrants further studies. Differential gene expression (basal and inducible) in tissue resident macrophages and monocyte-derived macrophages have been reported [22–27]. While differential expression/activation of intracellular signaling and metabolic state could be attributed to variable transcriptional upregulation of A20 by Nrf2, understanding distinct mechanisms underlying this process may aid in developing targeted strategies to mitigate inflammatory disorders.

Nrf2 is widely known to bind to the promoters of cytoprotective and cell survival genes and upregulate their transcription in response to oxidant stresses [28]. Mitigation of cellular stress by Nrf2 via induction of cytoprotective gene transcription is thought to play a key role in dampening excessive/chronic activation of pro-inflammatory cytokine gene expression exerted by damaged or necrotic cells in injured tissues. However, recently, it was shown that Nrf2 directly binds to the promoters of pro-inflammatory cytokines, including IL-1β and IL-6 [29] and suppresses their transcriptional induction by LPS in macrophages. Nrf2 mediates this function by attenuating RNA Polymerase II enrichment at the promoters, without affecting NF-κB binding and independent of reactive oxygen species levels, which are important for its (Nrf2) stabilization. Consistent with this result, we found increased levels of IL-1β expression in Nrf2-deficient LDMΦs treated with LPS (Figure 4). These results suggest that Nrf2 suppresses the inflammatory response in a
multi-faceted manner by directly controlling cytokine gene expression or indirectly by modulating expression of upstream negative regulators of pro-inflammatory signaling, such as A20.

Our study has certain limitations. Different culture conditions could affect macrophage cellular responses [30], as BMDMΦs are cultured for at least 5 days prior to treatment whereas LDMΦs are freshly isolated and immediately treated with LPS or TNFα. These culture conditions could, in part, explain the differences in Nrf2 mediated A20 induction by LPS. We performed mechanistic A20 expression regulation studies in macrophages at early time points post LPS or TNFα treatment (1–6 h), largely due to its rapid transcriptional activation and to assess Nrf2 direct effects, but not in response to chronic exposure or other inflammatory conditions. The pattern of A20 induction in BMDMs (Supplementary Figure S1) and LDMs (Supplementary Figure S2) by LPS is largely comparable between males and females. TNFα-stimulated A20 expression was greater in female LDMs than in male counterparts, but induction pattern overall showed a similar trend. As experiments with males and females were performed on different days, the observed mRNA expression differences need to be verified by treating macrophages from both genders with LPS/TNF side by side simultaneously in order to make any definite conclusions. Macrophages exhibit greater plasticity and heterogeneity with multiple phenotypic functions during inflammatory lung injury [31–34]. It is well established that both pro- and anti-inflammatory cytokine gene expression in macrophages is regulated in a tissue-specific and spatiotemporal manner [22,23]. Thus, the exact nature of A20 expression regulation by Nrf2 in different tissue resident and infiltrated macrophages in vivo during inflammatory lung injury and in chronic conditions require elaborative studies, including FACS and cell sorting as well as immunohistochemical analysis. The studies we have presented here can be elaborated upon to better define the nature/status of mechanisms controlling inflammatory response by Nrf2-A20 crosstalk in the context of clinical syndromes, such as ALI/ARDS, septic shock, and chronic diseases such as arthritis.

5. Conclusions

In summary, the present study demonstrates that Nrf2 acts as an upstream positive upregulator of anti-inflammatory cytokine signaling mediated by the A20 deubiquitinate, whose dysfunction or haplo-insufficiency leads to inflammatory disorders in mice and humans, respectively. Our results suggest that Nrf2 mediated A20 expression regulation in macrophages in response to acute pro-inflammatory mediators occurs distinctly in a tissue and cell type specific manner (i.e., monocyte-derived versus tissue resident macrophages). Based on these results and previous observations, we propose that Nrf2 directly counter-balances the unwarranted cytokine transcriptional response induced by oxidant stresses and pro-inflammatory stimuli in a multi-faceted manner in order to mitigate amplified inflammation and maintain homeostasis.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/antiox10060847/s1, Figure S1, LPS and TNFα-stimulated A20 mRNA expression in BMDMΦs isolated from Nrf2−/− male and female mice and WT counterparts; Figure S2, LPS and TNFα-stimulated A20 mRNA expression in LDMΦs isolated from Nrf2−/− and WT male and female mice; Figure S3, LPS-stimulated IL-1β mRNA expression in BMDMΦs and LDMΦs isolated from Nrf2−/− male and female mice and WT counterparts.

Author Contributions: Conceptualization, S.P.R.; methodology, H.R.P., L.K.V., C.R.T., A.A. and P.M.N.; validation and formal analysis, S.P.R., H.R.P., L.K.V., D.M., C.R.T., C.T. and P.M.N.; writing—original draft preparation, S.P.R.; writing—review and editing, S.P.R. and P.M.N.; supervision and project administration, S.P.R.; funding acquisition, S.P.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Institutes of Health R01GM124235 and R01 HL66109 (S.P.R.).
References

1. Boone, D.L.; Turer, E.E.; Lee, E.G.; Ahmad, R.C.; Wheeler, M.T.; Tsui, C.; Hurley, P.; Chien, M.; Chai, S.; Hitotsumatsu, O.; et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. *Nat. Immunol.* 2004, 5, 1052–1060. [CrossRef] [PubMed]

2. Ma, A.; Malynn, B.A. A20: Linking a complex regulator of ubiquitylation to immunity and human disease. *Nat. Rev. Immunol.* 2012, 12, 774–785. [CrossRef]

3. Das, T.; Chen, Z.; Hendriks, R.W.; Kool, M. A20/Tumor Necrosis Factor alpha-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models. *Front. Immunol.* 2018, 9, 104. [CrossRef]

4. Werner, S.L.; Kearns, J.D.; Zadorozhnaya, V.; Lynch, C.; O’Dea, E.; Boldin, M.P.; Ma, A.; Baltimore, D.; Hoffmann, A. Encoding NF-kappaB temporal control in response to TNF: Distinct roles for the negative regulators IkappaBalpha and A20. *Genes Dev.* 2008, 22, 2093–2101. [CrossRef]

5. Harhaj, E.W.; Dixit, V.M. Regulation of NF-kappaB by deubiquitinases. *Immunol. Rev.* 2012, 246, 107–124. [CrossRef] [PubMed]

6. Adrianto, I.; Wen, F.; Templeton, A.; Wiley, G.; King, J.B.; Lessard, C.J.; Bates, J.S.; Hu, Y.; Kelly, J.A.; Kaufman, K.M.; et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. *Nat. Genet.* 2011, 43, 253–258. [CrossRef] [PubMed]

7. Vereecke, L.; Beyaert, R.; van Loo, G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. *Biochem. Soc. Trans.* 2011, 39, 1086–1091. [CrossRef]

8. Wang, S.; Wen, F.; Wiley, G.B.; Kinter, M.T.; Gaffney, P.M. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. *PLoS Genet.* 2013, 9, e1003790. [CrossRef]

9. Lee, E.G.; Boone, D.L.; Chai, S.; Libby, S.L.; Chien, M.; Lodolce, J.P.; Ma, A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science* 2000, 289, 2350–2354. [CrossRef]

10. Zhou, Q.; Wang, H.; Schwartz, D.M.; Steffels, M.; Park, Y.H.; Zhang, Y.; Yang, D.; Demirkaya, E.; Takeuchi, M.; Tsai, W.L.; et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. *Nat. Genet.* 2016, 48, 67–73. [CrossRef] [PubMed]

11. Krikos, A.; Laherty, C.D.; Dixit, V.M. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. *J. Biol. Chem.* 1992, 267, 17971–17976. [CrossRef]

12. Oppipari, A.W., Jr; Hu, H.M.; Yabkowitz, R.; Dixit, V.M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. *J. Biol. Chem.* 1992, 267, 12424–12427. [CrossRef]

13. Tonelli, C.; Chio, I.I.C.; Tuveson, D.A. Transcriptional Regulation by Nrf2. *Antioxid. Redox Signal.* 2018, 29, 1727–1745. [CrossRef]

14. Baird, L.; Yamamoto, M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. *Mol. Cell. Biol.* 2020, 40, 40. [CrossRef]

15. Thimmulappa, R.K.; Lee, H.; Rangasamy, T.; Reddy, S.P.; Yamamoto, M.; Kensler, T.W.; Biswal, S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. *J. Clin. Investig.* 2006, 116, 984–995. [CrossRef]

16. Cho, H.-Y.; Jedlicka, A.E.; Reddy, S.P.M.; Kensler, T.W.; Yamamoto, M.; Zhang, L.-Y.; Kleeberger, S.R. Role of NRF2 in Protection Against Hyperoxic Lung Injury in Mice. *Am. J. Respir. Cell Mol. Biol.* 2002, 26, 175–182. [CrossRef]

17. Papaiaigliari, S.; Yerrapredddy, A.; Reddy, S.R.; Reddy, N.M.; Dodd, O.J.; Crow, M.T.; Grigoryev, D.N.; Barnes, K.; Tuder, R.M.; Yamamoto, M.; et al. Genetic and Pharmacologic Evidence Links Oxidative Stress to Ventilator-Induced Lung Injury in Mice. *Am. J. Respir. Crit. Care Med.* 2007, 176, 1222–1235. [CrossRef] [PubMed]

18. Reddy, N.M.; Kleeberger, S.R.; Kensler, T.W.; Yamamoto, M.; Hassoun, P.M.; Reddy, S.P. Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. *J. Immunol.* 2009, 182, 7264–7271. [CrossRef] [PubMed]

19. Mishra, R.K.; Potreti, H.R.; Tamamat, C.R.; Elangovan, I.; Reddy, S.P. c-Jun is Required for NF-kappaB-dependent, LPS-stimulated Fos-related Antigen-1 Transcription in Alveolar Macrophages. *Am. J. Respir. Cell Mol. Biol.* 2016, 55, 667–674. [CrossRef] [PubMed]

20. Aesif, S.W.; Anathy, V.; Kuipers, I.; Guala, A.S.; Reiss, J.N.; Ho, Y.S.; Janssen-Heininger, Y.M. Ablation of glutaredoxin-1 attenuates lipopolysaccharide-induced lung inflammation and alveolar macrophage activation. *Am. J. Respir. Cell Mol. Biol.* 2011, 44, 491–499. [CrossRef] [PubMed]

21. Shin, S.; Wakabayashi, N.; Misra, V.; Biswal, S.; Lee, G.H.; Agoston, E.S.; Yamamoto, M.; Kensler, T.W. NRF2 modulates aryl hydrocarbon receptor signaling: Influence on adipogenesis. *Mol. Cell. Biol.* 2007, 27, 7188–7197. [CrossRef] [PubMed]
22. Lavin, Y.; Winter, D.; Blecher-Gonen, R.; David, E.; Keren-Shaul, H.; Merad, M.; Jung, S.; Amit, I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 2014, 159, 1312–1326. [CrossRef] [PubMed]

23. Hussell, T.; Bell, T.J. Alveolar macrophages: Plasticity in a tissue-specific context. *Nat. Rev. Immunol.* 2014, 14, 81–93. [CrossRef] [PubMed]

24. Gautier, E.L.; Shay, T.; Miller, J.; Greter, M.; Jakubzick, C.; Ivanov, S.; Helft, J.; Chow, A.; Elpek, K.G.; Gordonov, S.; et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat. Immunol.* 2012, 13, 1118–1128. [CrossRef] [PubMed]

25. Redente, E.F.; Higgins, D.M.; Dwyer-Nield, L.D.; Orme, I.M.; Gonzalez-Juarrero, M.; Malkinson, A.M. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. *J. Leukoc. Biol.* 2010, 88, 159–168. [CrossRef] [PubMed]

26. Tighe, R.M.; Liang, J.; Liu, N.; Jung, Y.; Jiang, D.; Gunn, M.D.; Noble, P.W. Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. *Am. J. Respir. Cell Mol. Biol.* 2011, 45, 781–788. [CrossRef]

27. Lin, K.L.; Suzuki, Y.; Nakano, H.; Ramsburg, E.; Gunn, M.D. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. *J. Immunol.* 2008, 180, 2562–2572. [CrossRef]

28. Cho, H.Y.; Reddy, S.P.; Kleeberger, S.R. Nrf2 defends the lung from Oxidative Stress. *Antioxid. Redox Signal.* 2006, 8, 76–87. [CrossRef]

29. Kobayashi, E.H.; Suzuki, T.; Funayama, R.; Nagashima, T.; Hayashi, M.; Sekine, H.; Tanaka, N.; Moriguchi, T.; Motohashi, H.; Nakayama, K.; et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. *Nat. Commun.* 2016, 7, 11624. [CrossRef] [PubMed]

30. Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goedt, S.; Gordon, S.; Hamilton, J.A.; Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. *Immunity* 2014, 41, 14–20. [CrossRef] [PubMed]

31. Yona, S.; Kim, K.W.; Wolf, Y.; Mildner, A.; Varol, D.; Breker, M.; Strauss-Ayali, D.; Viukov, S.; Guilliams, M.; Misharin, A.; et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 2013, 38, 79–91. [CrossRef] [PubMed]

32. Guilliams, M.; Mildner, A.; Yona, S. Developmental and Functional Heterogeneity of Monocytes. *Immunity* 2018, 49, 595–613. [CrossRef] [PubMed]

33. Morales-Nebreda, L.; Misharin, A.V.; Perlman, H.; Budinger, G.R. The heterogeneity of lung macrophages in the susceptibility to disease. *Eur. Respir. Rev.* 2015, 24, 505–509. [CrossRef] [PubMed]

34. Gundra, U.M.; Girgis, N.M.; Ruckerl, D.; Jenkins, S.; Ward, L.N.; Kurzt, Z.D.; Wiens, K.E.; Tang, M.S.; Basu-Roy, U.; Mansukhani, A.; et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. *Blood* 2014, 123, e110–e122. [CrossRef] [PubMed]